Veracyte (VCYT) CFO Rebecca Chambers Sells 3,652 Shares

What Happened
Rebecca Chambers, Chief Financial Officer of Veracyte, reported sales and a tax-withholding related to vested restricted stock units. On Sept 4, 2026 she sold a total of 3,652 shares in two open-market transactions — 2,477 shares at an average price of $42.81 (≈ $106,030) and 1,175 shares at an average price of $43.71 (≈ $51,364), totaling about $157,394. Separately, on Sept 2, 2026, 3,603 shares were withheld to satisfy tax withholding obligations in connection with RSU vesting (reported at $44.88 per share, ≈ $161,703); that withholding is not a sale of shares.

Key Details

• Transaction dates: Sept 2, 2026 (tax withholding) and Sept 4, 2026 (open-market sales). Filing date: Sept 4, 2026. Filing appears timely.
• Sales breakdown: 2,477 shares @ $42.81 (weighted avg; prices in that lot ranged $42.49–$43.47) and 1,175 shares @ $43.71 (weighted avg; prices in that lot ranged $43.51–$44.16). Total proceeds ≈ $157,394.
• Tax withholding: 3,603 shares withheld on Sept 2 to cover tax obligations from RSU vesting; this withholding is not a market sale.
• Trading plan: Sales made under a Rule 10b5-1 plan adopted Aug 21, 2025.
• Shares owned after the transactions: not specified in the provided filing excerpt.

Context

• Sales under a 10b5-1 plan are pre-arranged trading programs and are often used to avoid timing concerns; they do not by themselves indicate a change in insider sentiment.
• The tax-withholding reflects RSU vesting (a non-sale disposition to cover taxes), not an open-market trade.
• For retail investors, purchases by insiders can carry more informational weight than routine sales or withholding events; these transactions appear routine and tied to compensation vesting and a pre-established trading plan.